CTOs on the Move

Beam Therapeutics

www.beamtx.com

 
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.beamtx.com
  • 26 Landsdowne Street 2nd Floor
    Cambridge, MA USA 02139
  • Phone: 857.327.8775

Executives

Name Title Contact Details
Brian Riley
 Senior Vice President of Technical Operations Profile
Brad Dutot
 Vice President, Information Technology Profile

Funding

Beam Therapeutics raised $13M on 04/27/2018
Beam Therapeutics raised $74M on 05/14/2018
Beam Therapeutics raised $11M on 03/06/2019
Beam Therapeutics raised $260M on 01/19/2021

Similar Companies

Evoke Pharmaceuticals

Evoke Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cabrellis

Cabrellis is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

National Vitamin Co

National Vitamin Company formulates, manufactures, tests, and distributes OTC Pharmaceuticals, Dietary Supplements, and Personal Care products for the global marketplace. The Quality Unit will define, devise, test, and enforce material standards and

Organic Cannabis Foundation

Organic Cannabis Foundation is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DynPort Vaccine Company

DynPort Vaccine Company LLC (DVC) provides an integrated approach for the advanced development of specific vaccines and other products to protect our nation against the threat of bio-warfare agents. This development effort includes process refinement,